Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. has completed a connected transaction to acquire an additional 10% equity stake in its affiliated finance company from SIIC Dongtan, raising its ownership in the finance entity to 40%. The completion of this acquisition, executed on the previously disclosed terms of the share transfer agreement, is expected to further consolidate Shanghai Pharmaceuticals’ control over its in-house financial services platform, potentially enhancing capital management efficiency and internal financing support for the group’s broader pharmaceutical operations, while also formalizing the transaction from a corporate governance and related-party perspective.
The most recent analyst rating on (HK:2607) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the manufacture, distribution and related services of medicines and healthcare products, with operations spanning both the pharmaceutical industrial and commercial sectors and a focus on the domestic PRC market and international expansion.
Average Trading Volume: 2,694,726
Technical Sentiment Signal: Buy
Current Market Cap: HK$66.62B
For a thorough assessment of 2607 stock, go to TipRanks’ Stock Analysis page.